ResMed (FRA:RMEA) ROCE % : 24.86% (As of Sep. 2024)

View and export this data going back to 2012. Start your Free Trial

What is ResMed ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. ResMed's annualized ROCE % for the quarter that ended in Sep. 2024 was 24.86%.

ResMed ROCE % Historical Data

The historical data trend for ResMed's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ResMed ROCE % Chart

ResMed Annual Data

Trend

Jun15

Jun16

Jun17

Jun18

Jun19

Jun20

Jun21

Jun22

Jun23

Jun24

ROCE %

Get a 7-Day Free Trial

21.51

22.58

25.35

21.87

22.00

ResMed Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
ROCE %	Get a 7-Day Free Trial															19.47	22.18	24.64	20.60	24.86

ResMed ROCE % Calculation

ResMed's annualized ROCE % for the fiscal year that ended in Jun. 2024 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Jun. 2024 )		(A: Jun. 2023 )		(A: Jun. 2024 )
	=	1217.46	/	( ( (6231.826 - 700.126)	+	(6384.454 - 845.998) )	/ 2 )
	=	1217.46	/	( (5531.7	+	5538.456)	/ 2 )
	=	1217.46	/	5535.078
	=	22.00 %

ResMed's ROCE % of for the quarter that ended in Sep. 2024 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2024 )		(Q: Jun. 2024 )		(Q: Sep. 2024 )
	=	1395.872	/	( ( (6384.454 - 845.998)	+	(6507.398 - 814.575) )	/ 2 )
	=	1395.872	/	( ( 5538.456	+	5692.823 )	/ 2 )
	=	1395.872	/	5615.6395
	=	24.86 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2024) EBIT data.

ResMed (FRA:RMEA) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

ResMed ROCE % Related Terms

Thank you for viewing the detailed overview of ResMed's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

ResMed Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » ResMed Inc (FRA:RMEA) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

RSMDF:USA RMD:USA RMD:Mexico 0KW4:UK RME:Germany RME:Germany R1MD34:Brazil RMD:Australia RMD:Austria

Address

9001 Spectrum Center Boulevard, San Diego, CA, USA, 92123

Website

https://www.resmed.com

ResMed is one of the largest respiratory care device companies globally, primarily developing and supplying flow generators, masks and accessories for the treatment of sleep apnea. Increasing diagnosis of sleep apnea combined with ageing populations and increasing prevalence of obesity is resulting in a structurally growing market. The company earns roughly two thirds of its revenue in the Americas and the balance across other regions dominated by Europe, Japan and Australia. Recent developments and acquisitions have focused on digital health as ResMed is aiming to differentiate itself through the provision of clinical data for use by the patient, medical care advisor and payer in the out-of-hospital setting.

ResMed Headlines

No Headlines